Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 211

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 211
---
 ​    ​                         
​                      ​   ​    ​         ​   ​      ​         ​       ​       ​        ​       ​    ​        ​   ​       ​    
Purchase commitments   ​   €    272,240   ​   €      189,662   ​       €       70,323   ​       €    10,962   ​   €       1,293
​
​

​
152

On December 31, 2023, we had outstanding obligations for purchase commitments, which become due as follows: 

         ​             ​   ​       ​      ​    ​        ​        ​       ​        ​        ​     ​      ​      ​     ​       ​  
--------------------------------------------------------------------------------------------------------------------------------
​                          Total              Less than                1 - 3                     3 - 5             More than 5  
                                              1 year                   years                     years             years        
​                      ​   ​    ​                              (Euro, in thousands)              ​    ​                         
Purchase commitments   ​   €    408,521   ​   €      237,495   ​       €       143,532   ​       €    25,768   ​   €       1,727
​
Our purchase commitments at the end of the year 2024 included €160.9 million related to projects in development phase (2023: €239.6 million), €60.9 million for projects in discovery research phase (2023: €79.0 million), €46.0 million for shared services (2023: €45.9 million), €1.7 million for commercial and medical affairs (2023: €29.9 million), and €2.6 million related to Jyseleca® product supply chain (2023: €14.2 million).
Effective July 1, 2023, under the terms of the agreement, our drug discovery and research activities conducted in Romainville, France, and our employees in Romainville, which were exclusively dedicated to the operation of these activities, were transferred to NovAliX who will assume all ongoing research and discovery activities in Romainville. In return, we are committed to utilizing the research capabilities and expertise of NovAliX through a five year-collaboration and within the context of the company’s R&D portfolio, during which we are committed to purchase for a total of €73.8 million services from Novalix. At year end 2024, our